FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to therapy and pulmonology, and concerns treating cystic fibrosis. That is ensured by administering a composition containing an effective amount of thymosin alpha-1 (Tα1), as a monotherapy or in combination with other anti-inflammatory agents.
EFFECT: providing effective treatment of cystic fibrosis by anti-inflammatory activity Tα1 and its ability to increase CFTR-mediated chloride transport in lungs.
18 cl, 9 dwg, 1 ex
| Title |
Year |
Author |
Number |
| USE OF CFTR MODULATORS FOR TREATING CEREBROVASCULAR CONDITIONS |
2019 |
|
RU2820288C2 |
| OLIGONUCLEOTIDES FOR MAKING CHANGE IN SEQUENCE OF TARGET RNA MOLECULE PRESENT IN LIVING CELL |
2013 |
- De Boer Deniel Anton
- Ritsema Tita
|
RU2663110C2 |
| STABLE COMPOSITIONS OF ASCORBIC ACID AND METHODS OF THEIR USE |
2018 |
- Kopland, Den
- Darem, Kerolin
|
RU2799046C2 |
| SOLID FORMS OF N-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL-)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUIINOLINE-3-CARBOXAMIDE |
2009 |
- Chzhan Behjli
- Kravets Mariush
- Botfild Martin
- Grotenkhejs Peter D J.
- Van Gur Fredrik
|
RU2518479C2 |
| NEW TREATMENT |
2015 |
- Ebbott-Banner Ketarin
- Khanrakhan Dzhon
- Tomas Devid
|
RU2688191C2 |
| INJECTION OF DEUTERATED CFTR AMPLIFIERS |
2016 |
|
RU2761344C2 |
| SOLID FORMS OF 3-(2, 2-DIFLUOROBENZO[D][1,3] DIOXOL-5-YL)CYCLOPROPANCARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID |
2011 |
- Keskhavarz-Skhokri Ali
- Chzhan Bejli
- Kravets Mariush
|
RU2579370C2 |
| GLUCOSIDASE INHIBITOR APPLICATION IN MUCOVISCIDOSIS THERAPY |
2004 |
- Bekk Frederik
- Nore Karolin
|
RU2358725C2 |
| NOVEL PEPTIDE-INHIBITOR PI3Kγ FOR TREATING RESPIRATORY DISEASES |
2015 |
- Khirsh Emilio
- Gigo Alessandra
|
RU2704826C2 |
| SOLID FORMS OF N-(4-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE |
2010 |
- Chzhan Behjli
- Kravets Mariush
- Luizi Brajan
- Medek Ales
|
RU2568608C2 |
